breast cancer - HR positive | |
la/mBC - HR-positive - 1st line (L1) | |
trastuzumab plus endocrine therapy | SYSUCC-002 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -